[blurbleblurble]

It's pretty awful though for a lot of people. Researchers outside of the US have published studies showing that s-ketamine has higher risk of dependency in animal experiments and lower long term efficacy for depression, like on par with placebo. If I'm remembering right there are a number of reasons for this and one of them is that r-ketamine seems to simulate neuroplasticity better, something related to BDNF in certain parts of of hippocampus I think?

While it probably works for some people, it's likely dangerous for many others.

Kenji Hashimoto and others have published numerous papers about this. It's not exactly under-researched. The incentives in the US are horribly misaligned.

Quite honestly it's upsetting that spravato even exists and there ought to be a huge class action lawsuit about this.

A few papers: https://pubmed.ncbi.nlm.nih.gov/32224141/ https://pubmed.ncbi.nlm.nih.gov/26327690/

[aarontait]

Yea, I agree. I wish there was some kind of organization that would seek FDA approval for racemic ketamine treatment of depression. It's cheap, and widely available. Unfortunately, without the incentive for a patentable product, it's unlikely to ever happen.